Roche wins FDA nod for tool in Hep C race; Acceleron advances blood-disorder drug;

 @FierceBiotech: In case you missed it yesterday: Sirtris co-founder fires back against resveratrol critics. Article | Follow @FierceBiotech

@JohnCFierce: J&J planning 5 new clinical studies for Xarelto, including CHF. | Follow @JohnCFierce

@RyanMFierce: Failed ALS study haunts Biogen in lawsuit from unhappy partner. Story | Follow @RyanMFierce

> Enanta Pharmaceuticals, a 2012 Fierce 15 company, focused on new hepatitis C compounds, has revealed terms for a $60 million IPO. Item

> Pfizer scraps development of hepatitis C candidate filibuvir as Gilead and AbbVie run free. More

> Acceleron began a Phase II study of its investigational protein therapeutic, ACE-536, to treat patients suffering from beta-thalassemia, a genetic hematologic disorder which causes chronic and life-threatening anemia. Release

> Gilead Sciences ($GILD), the top HIV drugmaker in the world, reported upbeat results from a mid-stage study of the HIV candidate TAF as Phase III development progresses. Release

> The FDA stamped an approval on Roche's ($RHHBY) test for the hepatitis C virus amid a surge in development of a new oral drugs against the liver-damaging disease. Article

> Mesoblast, a biotech from Down Under, is raising $153 million to develop a stem cell therapy for patients with degenerative spinal discs. Article (sub. req.)

Pharma News

@FiercePharma: In case you missed it: More job cuts at Merck as mfring in Rathdrum, Ireland, is phased out. 280 positions to go. Report | Follow @FiercePharma

@EricPFierce: JNJ withdraws 2.3 million packs of K-Y sex lubricants and won't bring them back. FDA says no safety risk. More | Follow @EricPFierce

> Patheon's Banner buyout adds to losses. Item

> Eisai fires back at G-BA rebuff of Fycompa. Story

> Bayer, J&J test Xarelto uses, even as ACS indication eludes. Article

> WHO finds Syrian situation grim, drug shortages critical. Report

Medical Device News

 @FierceMedDev: St. Jude eyes FDA approval with trial for stroke-stopping heart plug. News | Follow @FierceMedDev

 @MarkHFierce: Sequenom's Down Syndrome prenatal Dx juiced revenue tremendously in 2012. Release | Follow @MarkHFierce

 @DamianFierce: Florida's OrbusNeich is suing Boston Scientific, saying the device giant violated its stent patents. Story | Follow @DamianFierce

> Sequenom's prenatal Down syndrome Dx supercharges 2012 revenue. News

> Study: Excess weight-loss risks harming CRT-D heart failure patients. Report

> EpicGenetics rolls out first fibromyalgia-specific blood Dx. More

And Finally… Scans provide early peek at Alzheimer's years before the dementia destroys memory. Article

Suggested Articles

Novartis unveiled more data showing how its asthma combo QMF149 fared against the standard of care: a combination of the same types of drugs.

Johns Hopkins researchers developed a biodegradable polymer to transport large therapies into cells—including genes and even CRISPR.

UCB’s bispecific antibody recently beat Johnson & Johnson’s Stelara at clearing psoriasis symptoms, and now it has bested AbbVie’s Humira, too.